ARKG ETF ARK Genomic RevolutionHoldings, Performance and ETF Analysis
Last Week's Sector Review: Biotech / Genomics
Weekly Review (as of July 14, 2026) The Biotech / Genomics sector scored 0.118 this week, with a status of Risk Release, showing weak performance. Leading ETFs like ARKG, XBI, and IBB were dragged down by market sentiment, with biotech stocks under pressure. In a defensive market environment, high-risk, high-reward sectors are shunned. Looking ahead, focus on drug approvals and R&D progress; if innovation catalysts emerge, the sector may rebound. ---
Phase Tracking
Phase targets apply to the L1–L2 zone. Review window: 378 trading days.
Historical Phase Review
Reviews locked phase calls from the latest 378-session window.
How to Use the L-Lines
Trend structure:Four-line positioning helps frame whether the structure is weakening, stabilizing, or strengthening.
How to Read the Close Placement
Four-line positioning:Price versus the nearest upper and lower L-lines frames the current trend view and review zone.
Four-Line Fit Review
Reviews four-line fit against observed price behavior.
Full Fit Audit
Compares each fit axis with the global review baseline.
Recent Rolling Samples
Shows the latest reviewable samples.
Boundary Fit
Measures historical boundary fit.
Audit Downloads
Download backtest summaries, round details, charts, and audit records.